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Hepatitis C virus (HCV) readily sets up persistence in a large fraction of infected hosts.
Mounting epidemiological and immunological evidence suggest that HCV’s persistence
could influence immune responses toward unrelated pathogens and vaccines. Nonethe-
less, the fundamental contribution of the inflammatory milieu during persistent HCV
infection in impacting immune cells specific for common pathogens such as CMV and
EBV has not been fully studied. As the co-regulatory receptors PD-1, Tim-3, and 2B4 have
all been shown to be vital in regulating CD8+ T cell function, we assessed their expression
on CMV/EBV-specific CD8+ T cells from patients with chronic hepatitis C (CHC) and
healthy controls ex vivo and upon stimulation with virus-specific peptides in vitro. Total and
CMV/EBV-specific CD8+ T cells expressing PD-1, Tim-3, and 2B4 were highly enriched
in patients with CHC compared to healthy individuals ex vivo. In vitro peptide stimulation
further potentiated the differential co-regulatory receptor expression of PD-1, Tim-3, and
2B4, which then culminated in an enhanced functionality of CMV/EBV-specific CD8+
T cells in CHC patients. Comprehensively analyzing plasma cytokines between the two
cohorts, we observed that not only was IFNα-2a dominant among 21 other inflammatory
mediators elevated in CHC patients but it also correlated with PD-1 and Tim-3
expressions ex vivo. Importantly, IFNα-2a further caused upregulation of these markers
upon in vitro peptide stimulation. Finally, we could prospectively study patients receiving
novel IFN-free antiviral therapy. Here, we observed that treatment-induced clearance
of HCV resulted in a partial reversion of the phenotype of CMV/EBV-specific CD8+ T
cells in patients with CHC. These data reveal an alteration of the plasma concentrations
of IFNα-2a together with other inflammatory mediators during CHC, which appeared
to pervasively influence co-regulatory receptor expression on CMV/EBV-specific CD8+
T cells.
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Introduction
Chronic diseases caused by various pathogens impact a large pro-
portion of the global population. Recent updated global estimates
indicate that persistent infections with hepatitis C virus (HCV)
alone affect about 80 million infected individuals (1). Like for
many other viruses, antiviral T cell responses are particularly criti-
cal in limiting persistent infections and conferring lifelong protec-
tive immunity to viral re-exposures (2). In the majority of patients
with chronic hepatitis C (CHC), however, viral clearance often
fails as a result of an exhausted cytotoxic T cell response mediated
by several co-regulatory receptors such as PD-1, CTLA-4, Tim-3,
and 2B4 (3).Despite being functionally exhausted, T cell responses
during persistent HCV infection remain strong enough to cause
ongoing hepatocyte destruction (4). In the wake of the tissue
pathology that ensues, several intrahepatic immune-modulatory
cytokines (5) and chemokines (6) are induced.
Besides causing chronic intrahepatic inflammation and tis-
sue destruction, persistent HCV infection has been associated
with a plethora of extra-hepatic diseases, including autoimmune
TABLE 1 | Clinical characteristics of study cohorts.
Parameter Chronic HCV
(no therapy)
Chronic HCV
(sofosbuvir-treated)
Healthy
Time point Baseline
Number of subjects (n) 69 7 90
Number of HLA-A2
positive patients
61 7 67
Male sex – no. (%) 36 (52) 3 (43) N/A
Age (years)
Median 49 57 N/A
Range 22–80 53–67 N/A
HCV RNA – (IU/ml)
Median 1.2106 730,000 N/A
Range 8.6104–9.8106 1.8105–1.1107 N/A
8105 IU/ml – no./
total no. (%)
39/63 (62) 3/7 (43) N/A
Unknown 6/69 (9) N/A N/A
Undetectable 6/69 (9) N/A N/A
Alanine
aminotransferase – (U/l)
Median 71.5 67 N/A
Range 10–311 28–224 N/A
Above median – no./
total no. (%)
34/68 (50) 3/7 (43) N/A
Unknown 1/69 (1.5) N/A N/A
Aspartate
aminotransferase – (U/l)
Median 54.5 54 N/A
Range 22–279 27–118 N/A
Above median – no./
total no. (%)
34/68 (50) 3/7 (43) N/A
Unknown 1/69 (1.5) N/A N/A
HCV genotype – no. (%)
1 50 (82) 0 (0) N/A
2 2 (3) 1 (14) N/A
3 9 (15) 5 (72) N/A
5 0 (0) 1 (14) N/A
Not determined 8 (12) 0 (0) N/A
N/A, not applicable.
perturbations, lymphoproliferative disorders, diabetes, as well as
neurological complications (7). Accumulating epidemiological
evidence further suggests that persistent HCV infection might
impact the incidence as well as immune responses toward unre-
lated pathogens and vaccines. Particularly, immune responses
to vaccines against hepatitis A (8, 9), hepatitis B (10, 11), and
influenzaA (12) viruses are reduced in subjects with CHC. Similar
to what pertains in HCV-related neuropathy (13), it is conceivable
that the inflammatory mediators induced during persistent HCV
infection contribute to influencing immune responses to other
microbes. Indeed, an altered cytokine milieu was implicated in
the substantial skewing of T cell differentiation, proliferation, and
effector function observed in different settings of persistent virus
and parasitic infections in both animal models and human dis-
eases (11, 14, 15). Importantly, the impact of persistent infections
transcends those that are pathogen specific as they may also have
a global influence on the phenotype of the bulk T cell population
(16). In spite of all these strides, the contribution of the inflam-
matory milieu during persistent HCV infection in impacting the
phenotype and functional attributes of antigen-specific CD8+ T
cell responses toward common pathogens such as CMV and EBV
is not yet fully understood. So far, the limited data available on this
subject are conflicting. While some reports suggest that persistent
HCV infectionmay cause pervasive T cell intrinsic changes, which
influence the phenotype of circulating CMV-specific CD8+ T
cells (16, 17), others show otherwise (18).
In essence, we here evaluatedwhether persistentHCV infection
may influence the phenotype and functionality of CMV/EBV-
specific CD8+ T cells through distinct co-regulatory receptor
molecules. Our results reveal a profound HCV-induced alteration
of various inflammatory mediators, which appeared to influence
the frequency, phenotype, and in vitro functionality of both total
and virus-specific CD8+ T cells of CMV and EBV. Importantly,
these effects normalized upon treatment-inducedHCV clearance.
Materials and Methods
Study Subjects
A total of 154 subjects participated in this study. This included 76
patients with CHC recruited from the liver outpatient clinic and
78 healthy individuals comprising blood donors from the internal
blood donation center or healthy employees of the Hannover
Medical School undergoing routine check-ups. All patients were
anti-HIV andHBsAg negative and had no evidence of active CMV
or EBV disease. Of the patients with CHC, 69 had not received any
prior antiviral treatment, while 7 had received IFN-free antiviral
therapy with sofosbuvir+ ribavirin for 12–24weeks. Untreated
CHC patients had a compensated liver disease (13% cirrhosis)
and a median viral load, ALT and AST of 1.2 106 IU/ml, 71.5,
and 54.5U/l, respectively. The seven patients who had received
sofosbuvir therapy had cleared the virus at end of therapy, devel-
oped a sustained virologic response, and were non-cirrhotic and
normalized ALT and AST levels. For these patients, blood sam-
ples were collected at baseline (i.e., before therapy) and 12weeks
after end of therapy (FuW12). Patient cohorts and characteristics
are summarized in Table 1. The calculation of the absolute cell
numbers of CMV- and EBV-specific CD8+ T cells from patients
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with sofosbuvir treatment was performed using the frequencies
of multimer-positive CD8+ T cells referring to the lymphocyte
gate (frequency of lymphocytes) obtained by FACS analysis. The
total lymphocyte counts obtained from clinical hematological
diagnostics were used to calculate the absolute cell counts together
with the FACS frequencies obtained.
Isolation and Storage of PBMC and Blood
Plasma Samples
Peripheral blood mononuclear cells (PBMCs) were isolated
from fresh blood samples using standard Ficoll density gradi-
ent centrifugation. Cells were cryopreserved in freezing medium
consisting of 30% RPMI-1640 medium (Invitrogen, Karlsruhe,
Germany), 60% fetal bovine serum (PAA, Pasching, Austria), and
10% DMSO (Sigma-Aldrich, Munich, Germany). Blood plasma
sample collection was done from CPDA-treated blood samples
and stored at 20°C.
Peptides, HLA Class I Multimers, and
Recombinant Proteins
Antigenic HLA-A*0201 restricted CMV-specific pp65495–504
(NLVPMVATV) and EBV-specific BMLF1259–267 (GLCTLVAML)
peptides were purchased from ProImmune Ltd. (Oxford, UK).
Peptideswere dissolved in endotoxin-freeDMSO (Sigma-Aldrich,
Munich, Germany) and had a purity of >98%. Corresponding
PE-labeled MHC class I CMV tetramer as well as EBV Dextramer
were obtained from Beckman Coulter Inc. (Fullerton, CA,
USA) and Immudex (Copenhagen, Denmark), respectively. For
in vitro stimulations, PEG–IFN-alfa-2a (Pegasys; Roche) was
used. Additionally, lyophilized recombinant human ICAM-1 and
VCAM-1 were obtained from PeproTech Inc. (Rocky Hill, NJ,
USA) and reconstituted in 0.1% bovine serum albumin solution
according to the manufacturer’s instructions.
Fluorescent Antibodies and Phenotypical
Staining
The following mouse anti-human monoclonal antibodies (MAb)
were used: anti-PD1/clone EH12.2H7 (BioLegend Inc., SanDiego,
CA, USA), anti-2B4/clone C1.7 (Beckman Coulter, Fullerton,
CA, USA) as wells as anti-Tim3/clone 344823, and anti-human
IFNγ/clone 25723 (R&D Systems, Minneapolis, MN, USA). Anti-
CD14/clone M5E2, anti-CD19/clone 5J25C1, anti-CD56/clone
B159, anti-CD107b/clone H4B4, anti-TNF/clone MAb11, anti-
CD8/clone SK1, andmouse IgG isotype controls were all obtained
from BD Pharmingen (Becton Dickinson, Heidelberg, Germany).
Tetramer and antibody stainings were performed as detailed pre-
viously (19). Cells were acquired using a BD FACSCanto II flow
cytometer (Becton Dickinson, Heidelberg, Germany) and ana-
lyzed with FlowJo Software (TreeStar Inc., San Diego, CA, USA).
A multimer-specific CD8+ T cell population was considered
detectable if the frequency was at least 0.1% of total CD8+ T cells.
Exclusion of unspecific events was done using a dump channel
(CD14+CD19+CD56+). Respective FMOcontrols were included
to enable gating of cell populations.
In vitro Cellular Stimulation
Peripheral blood mononuclear cells were thawed and plated
at 3–4 105 cells/well in 96-well U-bottomed plates (Sarstedt
GmbH, Nümbrecht, Germany). Respective CMV- or EBV-
specific peptides at optimal concentrations (CMV: 1µg/ml,
EBV: 0.5µg/ml) were added to stimulate the cells. Conditions
of unstimulated cells were included as negative controls. All
cultures were kept in AB-Medium (RPMI-1640), 10% heat-
inactivated human AB serum (PAN Biotech GmbH, Germany),
1% non-essential amino acids, 1% sodium pyruvate, 1% peni-
cillin/streptomycin, 0.5% HEPES buffer (GIBCO), and supple-
mented with 5 IU/ml fresh human recombinant IL-2 (Invitrogen,
Karlsruhe, Germany) at day 3 and 7 during culture. For the
cytokine/chemokine stimulation assay, PBMCs were stimulated
with 10, 100, or 1000 ng/ml of ICAM-1, VCAM-1, or IFNα-2a in
the presence or absence of virus-specific peptides. In all cases, cells
were incubated at 37°C and 5% CO2 for 10 days.
Intracellular Cytokine Staining and CD107a
Degranulation Assay
After 10 days in vitro stimulation, PBMCs were resuspended
in fresh AB medium and incubated in the presence of opti-
mal concentrations of virus-specific peptides as described above.
Brefeldin A was added after 1 h and cells incubated for addi-
tional 5 h. Surface staining including CD107 was carried out
before intracellular staining for TNF and IFNγ was performed as
described (19).
Quantification of Plasma Cytokines and
Chemokines
The plasma concentrations of 50 cytokines and chemokines in
patients with CHC and healthy controls as well as CHC patients
treated with sofosbuvir were measured using the Luminex-
based multiplex technology (Bio-Plex Pro Human Cytokine
Panel, Bio-Rad, Hercules, CA, USA). The assay was per-
formed as per the manufacturer’s instructions. Briefly, lyophilized
cytokine/chemokine standards were resuspended in standard
diluents and a series of serial dilutions performed in order
to generate standard curves for each cytokine/chemokine. Fifty
microliters of the resuspended standard cytokine/chemokine or
plasma samples were pipetted and incubated for 30min at RT
with a mixture of beads having specificity for each cytokine or
chemokine. The beads were washed several times with wash
buffer. Biotinylated secondary antibody mixture was added and
incubated for 30min at RT, washed three times, before stain-
ing with streptavidin-conjugated R-phycoerythrin (SAPE). Beads
were washed three times and resuspended in 125µl assay buffer,
acquired and analyzed using the BioPlex Manager 6.0 software.
Our internal standard operating procedure for data analysis is
available upon request.
Statistical Analyses
Data were analyzed using GraphPad Prism v6.0b (GraphPad
software, La Jolla, CA, USA). Quantitative comparisons were
performed using parametric or non-parametric Student’s t-test.
p Values of <0.05 were considered to be significant (*p< 0.05;
**p< 0.01; ***p< 0.001; ****p< 0.0001). Correlations were cal-
culated using the Pearson correlation coefficient test. Principal
component analysis (PCA) was conducted using Qlucore Omics
Explorer v3.0 (Qlucore AB, Lund, Sweden). In the PCA model,
t-test was used to compare two groups.
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Ethics Statement
Written informed consent was obtained in all cases as part of
protocols approved by the local ethics committee of the Hannover
Medical School. All investigations conformed to the principles
espoused in the Declaration of Helsinki.
Results
CD8+ T Cells from Patients with CHC Show
Elevated Co-Regulatory Receptor Expression
In a previous report, we demonstrated that the co-regulatory
receptor 2B4 was increased in expression in patients with CHC
compared to healthy individuals (20). To extend this further
and investigate how a broader array of co-regulatory receptor
expressions are influenced by a persistent HCV infection, fre-
quencies of total CD8+ T cells expressing PD-1, Tim-3, and
2B4 were assessed in patients with CHC and healthy controls
ex vivo (Figures 1A,B). Patients with CHC displayed signifi-
cantly higher frequencies of PD-1-, Tim-3-, and 2B4-expressing
CD8+ T cells compared to healthy controls (Figure 1B). While
the frequency of PD-1-expressing CD8+ T cells was 1.70-fold
higher in patients with CHC, that of Tim-3 and 2B4 were
1.65 and 1.49-fold, respectively, higher as compared to healthy
donors.
To specifically evaluate the expression patterns of PD-1, Tim-
3, and 2B4 on antigen-specific CD8+ T cells in both cohorts, we
focused on CMV and EBV; two common human pathogens with
large CD8+ T cell memory pools that are easily detectable ex vivo.
Patients with CHC harbored significantly higher frequencies of
CMV- andEBV-specific CD8+ Tcells ex vivo in relation to healthy
individuals (Figure 1C). In fact, we evaluated the cohort CHC
only as those from the healthy blood donors were unavailable
for regulatory reasons. We observed that the frequency of CMV-,
but not EBV-specific CD8+ T cells ex vivo positively correlated
with age (data not shown). When the direct ex vivo expression
of co-regulatory receptor molecules on CMV-specific CD8+ T
cells was compared between patients with CHC and healthy indi-
viduals, we observed that the frequencies of PD-1-, Tim-3-, and
2B4-expressing CMV-specific CD8+ T cells were significantly
increased in the latter (Figure 1D). A similar observation was
made for EBV-specific CD8+ T cells (Figure 1E). Unsurpris-
ingly, the simultaneous co-expression of all three co-regulatory
receptors was similarly up-regulated on CMV- and EBV-specific
CD8+ T cells in CHC patients compared to healthy individuals
(data not shown). To further investigate whether age is associ-
ated with co-regulatory receptor expression, we used data from
patients with CHC. Here, no correlation was observed between
co-regulatory receptor expression and age. Patients with CHC
FIGURE 1 | Expression of co-regulatory receptors on total and
CMV/EBV-specific CD8+ T cells in CHC patients and healthy controls ex
vivo. (A) Exemplary FACS staining showing the gating strategy used to identify
total and MHC-I multimer-positive virus-specific CD8+ T cells. (B) Expression of
PD-1, Tim-3, and 2B4 is elevated on total CD8+ T cells in patients with CHC
(n= 36 for PD-1 and Tim-3, n= 46 for 2B4) compared to healthy individuals
(n= 54 for PD-1 and Tim-3, n= 31 for Tim-3). (C) Frequencies of CMV- and
EBV-specific CD8+ T cells are elevated in patients with CHC (n= 36 for CMV
and n= 38 for EBV) compared to healthy individuals (n= 34 for CMV and
n= 49 for EBV). Expression of PD-1, Tim-3, and 2B4 is elevated on
(D) CMV-specific (Healthy:CHC, PD-1 n= 34:25, Tim-3 n= 16:25, 2B4
n= 34:36) and (E) EBV-specific CD8+ T cells (Healthy:CHC, PD-1 n= 32:30,
Tim-3 n= 29:30, 2B4 n= 49:38) in these CHC patients compared to the
healthy blood donors. Red horizontal bars indicate mean values. Representative
FACS plots are shown. Cells were gated on lymphocytes and total CD8+ T cells
after exclusion of dump channel.
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were further categorized into two groups: young (<50 years) and
old (>50 years). We still did not observe any differences in co-
regulatory receptor expression between the two groups (data not
shown). In summary, persistent infection with HCV was associ-
ated with an altered phenotype of both bulk and CMV- and EBV-
specific CD8+ T cells ex vivo with a shift toward co-regulatory
receptor upregulation.
In vitro Peptide Stimulation Pronounces the
Differential Co-Regulatory Receptor Expression
on CMV-/EBV-Specific CD8+ T Cells in Patients
with CHC
Next, we investigated the dynamics of co-regulatory receptor
expression on CMV- and EBV-specific CD8+ T cells from the
two cohorts upon peptide stimulation. PBMCs from randomly
selected patients of either cohort were stimulated with virus-
specific peptides in vitro for 10 days and subsequently stainedwith
MHC class I multimers. The expression of PD-1, Tim-3, and 2B4
was investigated. Overall, CMV- and EBV-specific CD8+ T cells
showed a similar expression pattern with no significant differ-
ences between them as demonstrated in Figure 1. We therefore
performed all subsequent analyses with the two cell populations
together. Evaluating the two virus-specific CD8+ T cell popula-
tions together, we observed that the expression of PD-1 and Tim-3
was particularly up-regulated upon peptide stimulation in vitro
(Figures 2A,B and 2D,E; Figure S1 in Supplementary Material).
This pattern of response was observed irrespective of the sample
source; CHC patients or healthy blood donors. However, the com-
parative potentiation of PD-1 and Tim-3 expressions was stronger
for CMV- and EBV-specific CD8+ T cells in CHC patients than
in healthy individuals (Figures 2A,B and 2D,E). This was evident
in the superior fold increases in the CHC patients (PD-1= 1.82-
fold, Tim-3= 3.72-fold) compared to the healthy controls (PD-
1= 1.36-fold, Tim-3= 3.16-fold). The expression of 2B4 was
down-regulated but this was only noticeable on CMV- and EBV-
specific CD8+ T cells in healthy individuals (fold decrease= 0.68)
compared to patients with CHC where they remained fairly
stable (fold increase= 1.01; Figures 2C,F; Figure S1 in Supple-
mentary Material). These data indicate that the inflammatory
milieu in CHC patients may precondition CMV- and EBV-
specific CD8+ T cells to up-regulate co-regulatory receptor
expression.
CMV-/EBV-Specific CD8+ T Cells from CHC
Patients Display an Elevated Proliferation and
Cytokine Production
In the light of the dichotomy between the dual roles of co-
regulatory receptor expression in T cell exhaustion and acti-
vation, we next assessed the proliferative, cytokine-producing,
and cytotoxic capacities of peptide-stimulated CMV- and EBV-
specific CD8+ T cells from the two cohorts. The prolifera-
tion of CMV- and EBV-specific CD8+ T cells was significantly
FIGURE 2 | Effect of in vitro peptide stimulation on co-regulatory
receptor expression by CMV-/EBV-specific CD8+ T cells in patients
with CHC and healthy individuals. A comparison of the mean
fluorescence intensities (MFI) of (A) PD-1, (B) Tim-3, and (C) 2B4
expressions on CMV-/EBV-specific CD8+ T cells in healthy individuals
(n= 12 for CMV; n= 10 for EBV) and patients with CHC (n= 12 for CMV,
n= 14 for EBV) revealed a stronger increase of expression in CHC patients
upon peptide stimulation in vitro. Indicated are individual values of
co-regulatory receptor expression ex vivo and upon culture in vitro. Red
horizontal bars indicate mean values. The increase of expression was also
revealed by comparing the fold increase of expression of (D) PD-1,
(E) Tim-3, and (F) 2B4 upon in vitro peptide stimulation in relation to the ex
vivo expression. p-Values are indicated. Cells were gated on lymphocytes
and total CD8+ T cells after exclusion of dump channel.
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enhanced in patients with CHC compared to healthy individuals
(Figures 3A,B; Figures S2A and S3A in Supplementary Material).
This was evident in the 2.23-fold higher expansion observed in
CHC patients (mean fold increase= 49.78) in relation to that of
healthy individuals (mean fold increase= 22.35). Similarly, the
mean fold increases of IFNγ and TNF production as well as
CD107a/b expression (a surrogate marker for cytotoxicity) were
all stronger in patients with CHC (37.54, 21.36, and 35.81-fold,
respectively) compared to healthy controls (9.49, 4.16, and 2.02-
fold, respectively) (Figures 3C–E; Figures S2B–D, S3B–D, and
S4 in Supplementary Material). This suggests that the stronger
induction of co-regulatory receptor expression by CMV- and
EBV-specific CD8+ T cells upon in vitro peptide stimulation may
culminate in an enhanced proliferation and functional responses
rather than attenuating them.
This observation of an enhanced co-regulatory receptor expres-
sion on CD8+ T cells and their nevertheless strong functional
capacity is contrary to the often described and accepted inhibitory
effect of PD-1 and Tim-3 and partially also 2B4. Indeed, to show
that the co-regulatory receptor-positive cells might nevertheless
effectively proliferate, we grouped the samples of healthy and
CHC individuals according to their ex vivo frequencies of expres-
sion of PD-1, Tim-3, and 2B4 into high and low groups. Here,
all these groups showed a similar proliferation of CMV- and
EBV-specific CD8+ T cells (data not shown), no differences in
proliferative responses in correlation to the expression of these
co-regulatory receptors were apparent in healthy individuals or
CHC patients.
Plasma Cytokine Patterns Differ Between CHC
Patients and Healthy Individuals and Correlate
with Expression of Co-Regulatory Receptor
Expression
The foregoing findings prompted us to investigate the possible
mechanism behind the altered phenotype and function of CD8+
T cells in persistent HCV infection as observed. As cytokines and
chemokines produced during chronic inflammation in patients
with CHC may substantially influence immune cells, we aimed
to investigate their possible contribution. Thus, we quantified
several cytokines and chemokines (n= 50) in the plasma of
patients with CHC and healthy individuals using a multiplex
bead assay. Using PCA, the differential concentrations of different
cytokines and chemokines in CHC patients and healthy indi-
viduals resulted in a distinct clusterization of members of each
cohort (Figure 4A). Particularly, inflammatory mediators and
proteins, such as IFNα2, IL-3, SCF, IL-2Rα, CTACK (CCL27),
TRAIL (CD253), VCAM-1 (CD106), IL-12p40, MCP-3 (CCL7),
M-CSF, RANTES (CCR5), IP-10 (CXCL10), ICAM-1 (CD54),
HGF, SCGF-β, MIG (CXCR3), MIP-1β (CCL4), IL-18, G-CSF,
LIF, SDF-1α (CXCL12), and VEGF, were all significantly ele-
vated in patients with CHC as compared to healthy individuals
(Figure 4B). Other mediators including IL-17, MIF, GROα, and
FGF were, however, down-regulated in patients with CHC. To
identify a possible link to the phenotype of CD8+ T cells, we
then performed correlation analyses between the levels of plasma
cytokines and chemokines and co-regulatory receptor expression
FIGURE 3 | Proliferation and cytokine production in vitro by
CMV-/EBV-specific CD8+ T cells from CHC patients and healthy
individuals. PBMCs from patients with CHC (n= 32) and healthy individuals
(n= 28) were stimulated with CMV- or EBV-specific peptides in vitro for 10 days.
(A) Representative FACS plots for staining of CMV- and EBV-specific CD8+ T
cells and (B) pooled data show an increased fold expansion of CMV-(Healthy:
CHC, n= 16:13) and EBV-(Healthy:CHC, n= 16:15) specific CD8+ T cells in
CHC patients compared to healthy individuals. (C) Fold increases of IFNγ- and
(D) TNF production as well as (E) CD107-expression on CMV-(Healthy:CHC,
n= 14:11) and EBV-(Healthy:CHC, n= 13:13) specific CD8+ T cells upon
stimulation with CMV- or EBV-specific peptides in vitro were stronger in CHC
patients as compared to healthy controls. Graphs on the left hand side show
fold increases induced by peptide stimulation in comparison to unstimulated
(medium only) controls. Right hand graphs show individual absolute frequencies
for healthy individuals and CHC patients found for medium controls and
peptide-stimulated cells. Red horizontal bars indicate mean values. Cells
were gated on lymphocytes and total CD8+ T cells after exclusion of dump
channel.
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FIGURE 4 | Differences of and association of plasma
cytokine/chemokine levels with ex vivo expression of distinct
co-regulatory receptors on CMV/EBV-specific CD8+ T cells in CHC
patients. Fifty cytokines and chemokines were measured in the plasma of CHC
patients without prior treatment and healthy controls by a multiplex assay.
(A) Principal component analysis showed a distinct clusterization of CHC
patients (blue) and healthy individuals (yellow) based on the differential
concentrations of plasma cytokines and chemokines. (B) Heat map comparing
plasma cytokine/chemokine levels showed cytokines and chemokines with
significantly differential concentrations between CHC patients and healthy
individuals. (C) Correlation analysis of IFN-α2, VCAM-1 (CD106), and ICAM-1
(CD54) with co-regulatory receptor expression revealed a positive correlation of
IFN-α2 plasma levels with PD-1 and Tim-3 expression ex vivo. Each patient’s
FACS data were correlated individually to the same patient’s cytokine data
obtained from the multiplex assay. p- and r2-values are indicated. Cells were
gated on lymphocytes and total CD8+ T cells after exclusion of dump channel.
on CMV- and EBV-specific CD8+ T cells ex vivo on an individ-
ual basis comparing the respective patient’s FACS data with the
cytokine values obtained from the multiplex assay (Figure 4C).
For representation purposes, we selected the three recombinant
human proteins VCAM-1, ICAM-1, and IFNα-2a that were fur-
ther used for in vitro stimulation experiments. These proteinswere
selected based on their elevated plasma levels in CHC patients,
literature-proven T cell co-stimulatory effects inducing cell sig-
naling, presence of their respective receptors on T cells as well as
their correlation with PD-1, Tim-3, or 2B4 ex vivo expression. Our
results demonstrated a significant positive correlation of IFNα-2a
plasma levels with PD-1 and Tim-3 expressions (Figure 4C). The
seemingly positive correlation between IFNα-2a and 2B4 expres-
sions, however, did not reach statistical significance. Apart from
IFNα-2a other components of the HCV-induced inflammatory
milieu such as IP-10, SDF, RANTES, SCF, and IL-18 positively
correlated with at least one of PD-1, Tim-3, or 2B4 expression ex
vivo (data not shown). By contrast, no correlation was observed
between plasma concentrations of VCAM-1 and ICAM-1 (two
adhesion molecules that were also up-regulated in CHC patients)
with PD-1, Tim-3, or 2B4 expression (Figure 4C). These results
hinted a role of IFNα-2a in influencing co-regulatory receptor
upregulation on CMV- and EBV-specific CD8+ T cells in patients
with CHC.
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In vitro IFNα Stimulation Converted the
Phenotype of CMV-/EBV-Specific CD8+ T Cells in
Healthy Individuals to Those in Patients with CHC
To further investigate whether the alterations of PD-1,
Tim-3, and 2B4 expression patterns are indeed induced by
cytokine/chemokine stimulations, we stimulated PBMC in vitro
from healthy blood donors with different concentrations of
selected recombinant human proteins for 10 days in the presence
of CMV- or EBV-specific peptides. Our selected recombinant
human proteins included VCAM-1, ICAM-1, and IFNα-2a.
Here, our aim was to assess the ability of the selected soluble
mediators to convert the phenotype of CMV- and EBV-specific
CD8+ T cells from healthy donors into those that were found
in patients with CHC. In our analyses, no effect of VCAM-1
or ICAM-1 stimulation on the expression of PD-1, Tim-3, or
2B4 on CMV- and EBV-specific CD8+ T cells was evident
(Figure 5A). Interestingly, however, stimulation with IFNα-2a
in vitro resulted in a consistent dose-dependent upregulation of
PD-1 and Tim-3 expressions. This was reflected not only in the
frequencies of positive cells but also in the expression levels (MFI)
FIGURE 5 | Effect of in vitro cytokine/chemokine stimulation on the
phenotype of CMV- and EBV-specific CD8+ T cells in healthy blood
donors. Expression of PD-1, Tim-3, and 2B4 was analyzed on CMV- and
EBV-specific CD8+ T cells in PBMC from healthy blood donors (n=16) after
stimulation with selected proteins together with virus-specific peptides.
(A) Stimulation with different concentrations of VCAM-1 (CD106) or ICAM-1
(CD54) did not alter the expression of PD-1, Tim-3, or 2B4 on
CMV-/EBV-specific CD8+ T cell responses (n= 13). (B) Representative FACS
histogram overlays showing the frequencies and the expression intensities
(MFIs) of PD-1, Tim-3, and 2B4 upon stimulation with different concentrations of
IFN-α2. One healthy individual is shown as representative. Stimulation with
IFNα-2 in vitro resulted in a consistent upregulation of both the frequency (left)
and MFI (right) of (C) PD-1, and (D) Tim-3 expression or (E) down-regulation of
2B4 expression on CMV-/EBV-specific CD8+ T cells in a dose-dependent
manner. In vitro stimulation assay with VCAM-1 and ICAM-1 was performed in a
separate experiment from that with IFNα-2. Red horizontal bars indicate mean
values. Cells were gated on lymphocytes and total CD8+ T cells after exclusion
of dump channel.
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(Figures 5B–D). The expression of 2B4 on IFNα-stimulated
CMV- and EBV-specific CD8+ T cells in healthy individuals
was reminiscent of the phenotype we observed earlier in CHC
patients (Figure 5E). Although Tim-3 expression was marginally
up-regulated, stimulation of PBMCs from healthy individuals
with only IFNα-2a without any virus-specific peptides, however,
did not result in any considerable effect suggesting an antigen-
dependent effect of IFNα-2a stimulation on the modulation of
T cell co-regulatory receptor expression (data not shown).
Treatment-Induced HCV Clearance Resulted in a
Partial Reversion of the Phenotype of
CMV-/EBV-Specific CD8+ T Cells
Our previous data demonstrated that the cytokine milieu can
impact the phenotype of CMV- and EBV-specific CD8+ T cells
leading to an enhanced expression of co-regulatory molecules.
We next asked whether an antiviral therapy-induced clearance of
HCV RNA would then lead to a reversion of the phenotype of
CMV- and EBV-specific CD8+ T cells to that found in healthy
individuals by causing a decrease in PD-1, Tim-3, and 2B4 expres-
sions. To address this, we used PBMC from seven patients with
CHC who had undergone successful antiviral treatment based on
the novel IFN-free sofosbuvir administration. CMV- and EBV-
specific CD8+ T cells from these samples were analyzed ex vivo at
baseline (before treatment) and follow-up week 12 (FuW12). We
did not observe any differences in the frequency of CMV-/EBV-
specific CD8+ T cells between baseline and FuW12 ex vivo and
also not in the absolute cell count of these cells (Figure 6A). This
observation was the same for both CMV- and EBV-specific CD8+
T cells, demonstrating that the survival of these cells is not affected
by the treatment. However, comparing the co-regulatory recep-
tor expression between the two time points, we could observe
a significant reduction in both the frequency (%) and MFI of
PD-1 expression at FuW12 (Figures 6B,C). The frequency of Tim-
3-expressing CMV-/EBV-specific CD8+ T cells also decreased
significantly at FuW12, although this was not reflected in theMFI
(Figure 6D). The expression of 2B4 remained almost unaltered
between baseline and FuW12 except for a borderline signifi-
cance, which was recorded for its MFI (Figure 6E). In accordance
with this, the plasma levels of cytokines/chemokines measured
by multiplex assay changed upon therapy-induced resolution of
infection (data not shown). Importantly, IFNα levels decreased
significantly until FuW12 (Figure 6F), which is in correlation to
the observed change of the phenotype of CMV- and EBV-specific
CD8+ T cells. Overall, this data further strengthen the hypothesis
that the phenotype of CMV- and EBV-specific CD8 T+ cells
is affected by the inflammatory cytokine milieu present during
persistent HCV infection.
Discussion
Overexpression of distinct co-regulatory receptors such as PD-1,
CTLA-4, Tim-3, Lag-3, and 2B4 has been previously described
and strongly considered as a fingerprint for exhausted T cells.
Particularly, in many persistent virus infections where T cells
have been shown to have an impaired proliferative capacity
FIGURE 6 | Phenotypic characterization of co-regulatory receptor
expression by CMV-/EBV-specific CD8+ T cells ex vivo in CHC patients
clearing the infection upon antiviral therapy. PBMCs from seven patients
who had cleared HCV infection after receiving IFN-free antiviral therapy with
sofosbuvir were analyzed at baseline (BL) and 12weeks after end of therapy
(FuW12). (A) Absolute frequencies (left) and absolute cell numbers (right) of
CMV-/EBV-specific CD8+ T cells ex vivo did not significantly differ between
baseline and FuW12. (B) Representative FACS histogram overlays showing
staining of PD-1, Tim-3, and 2B4 expressions on EBV-specific CD8+ T cells ex
vivo showing a partial decrease of expression at FuW12 (blue line) as compared
to baseline (red line). A loss of the frequencies (left) and mean fluorescence
intensity (right) of (C) PD-1, (D) Tim-3, and (E) 2B4 expressions on
CMV-/EBV-specific CD8+ T cells was visible at FuW12 indicating a loss and
thus partial reversion of their phenotype upon antiviral treatment for HCV.
(F) Plasma IFN-α2 levels at baseline and FuW12 were analyzed by multiplex
assay revealing a significant reduction of IFN-α2 levels upon therapy-induced
clearance of HCV. Cells were gated on lymphocytes and total CD8+ T cells
after exclusion of dump channel.
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and functionality, upregulation of various co-regulatory receptors
have been observed. In this context, it has been suggested that
co-regulatory receptor overexpression is a way the immune sys-
tem prevents uncontrolled inflammation and pathology due to
the constant antigen stimulation. However, antigen stimulation
alone does not seem to be the only driving force behind co-
regulatory receptor upregulation. Indeed, several studies have
demonstrated both antigen-dependent and -independent mecha-
nisms that are capable of increasing co-regulatory receptor expres-
sion. For example, antigen specificity, cell differentiation, and the
microenvironment were found to strongly influence the expres-
sion of co-regulatory receptors on CD8+ T cells (21–23). Using
HCV as a model of persistent virus infection in humans, we
comprehensively investigated the influence inflammatory medi-
ators induced during persistent infections have on co-regulatory
receptor expression by CD8+ T cells specific for the common
pathogens CMV and EBV. Both CMV and EBV are particularly
ubiquitous in the human population where they usually have a
lifelong persistence in the infected host. Virus-specific CD8+ T
cell populations targeting the two viruses are often larger and ex
vivo detectability is high. These attributes informed our choice
of studying the two viruses and afforded us the opportunity to
examine the effects of HCV’s persistence on an unrelated antigen-
specific T cell population in clear, unambiguous terms using the
MHC-I multimer technology.
Evaluating co-regulatory receptor expression by antigen-
specific CD8+ T cells, we observed that PD-1-, Tim-3-, and 2B4-
expressingCMV- andEBV-specific CD8+ T cells were enriched in
patients with CHC compared to their counterparts in uninfected
controls. The increased frequencies of CMV-specific CD8+ T cells
expressing Tim-3 in patients with CHC compared to uninfected
controls was previously shown (24). Our findings here, derived
from a larger group of patients, thus confirm and significantly
extend the previous report even further with two additional co-
regulatory molecules (PD-1 and 2B4) prominent in persistent
infections. We further observed that persistent HCV infection
not only influenced co-regulatory receptor expression by antigen-
specific CD8+ T cells of viruses unrelated to HCV but also
impacted the phenotype of total CD8+ T cells. The strikingly
high expression of PD-1, Tim-3, and 2B4 by the total CD8+ T
cell population in persistent HCV infection is indicative of the
pervasive global influence persistent HCV has on the phenotype
of T cells, beyond those that are HCV-specific. We further have
data published recently showing that the enhanced functional-
ity of immune cells during CHC is not restricted to CD8+ T
cells, but that a similar elevated functionality can be observed for
NK cells as well (25). Certainly, these observations called into
question the actual role of co-regulatory receptor expression on
antiviral T cell immunity in disease. Indeed, the association of
functional exhaustion to the elevated expression of co-regulatory
receptors in patients with CHC has been well established (3, 26).
However, apart from this report, high PD-1 and 2B4 expressions
on functionally competent CMV- and/or EBV-specific CD8+ T
cells in patients with CHC have also been demonstrated before
(16, 20, 27). Moreover, we demonstrated in a recent report that
PD-1 and 2B4 expressions by CMV- and EBV-specific CD8+ T
cells in patients with CHC were significantly higher compared to
exhausted HCV-specific CD8+ T cells in the same patients (28).
Again, Kroy et al. who extensively characterized co-regulatory
receptor expression on CD8+ T cells on IHLs also revealed that
IHLs from liver tissue without infection, inflammation, or malig-
nancy displayed the same patterns of PD-1 and 2B4 expressions as
those with HCV infection (22). Strengthened by previous obser-
vations, our findings here therefore water down the heightened
assumption and reference of co-regulatory receptor molecules as
“classical markers of exhaustion.” Further, it strongly supports
the notion that enrichment of co-regulatory receptor expression
(especially PD-1 and 2B4)may be amere physiological response to
the microenvironment and not necessarily a reflection of a failing
immune response in disease.
In many persistent virus infections, the expression of multiple
co-regulatory receptors has been tightly linked to a reduced prolif-
eration and cytokine production (29, 30). In recent years, however,
it is becoming increasingly evident that co-regulatory receptor
expression may not solely drive the functional impairment of
effector CD8+ T cells. Many independent investigations have oth-
erwise shown that co-regulatory receptor-positive CD8+ T cells in
peripheral blood of healthy donors are not necessarily functionally
impaired (23, 31, 32). Instead, PD-1 expression correlated with
positive T cell function and with activationmarkers such as CD38
in HIV infection as reviewed in Ref. (33) or CD137 in breast can-
cer studies (34). Guided by these observations, we sought to ascer-
tain the functional consequence of theHCV-induced upregulation
of PD-1, Tim-3, and 2B4 on the CMV- and EBV-specific CD8+ T
cells in CHC patients compared to healthy donors. We observed
significantly enhanced functional responses upon peptide stimu-
lation, which was distinctive to CMV- and EBV-specific CD8+ T
cells exposed to the inflammatorymilieu in persistent HCV infec-
tion. Ostensibly, this observation was made concomitant to a rel-
ative upregulation of co-regulatory receptor expression through
TCR stimulation with cognate peptides in vitro. This observation
was exceptionally interesting as it particularly linked immune
activationwith co-regulatory receptor upregulation and improved
functional responses (at least for CMV- and EBV-specific CD8+
T cells) as has been suggested before (23). Further, stratifying our
samples by the ex vivo expression levels of co-regulatory receptors
revealed that there is no difference in the in vitro proliferative
responses between ex vivo low and high expressing samples and
this held true for both healthy individuals and CHC patients.
Overall, these observations suggest that PD-1 or Tim-3 expression
per sedonot necessarilymakeT cells exhausted anddysfunctional,
but that additional and so far unknown events appear to be crucial
to convert these molecules into actual inhibitors. Further, these
data point to a much profound conditioning of CMV- and EBV-
specific CD8+ T cells by the inflammatory milieu in patients with
CHC, which alters co-regulatory receptor expression, and the cells
benefiting thereof with an improved functional responses.
The changes in phenotype and function during CHC were
visible and common for both CMV- and EBV-specific CD8+ T
cells with no major differences apparent. This suggests that broad
and general factors seem to drive these changes and not virus-
specific ones. This becomes especially important in the light of
a recent publication showing that CMV infection is one of the
major non-heritable factors impacting the immune phenotype
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and response in humans (35). Despite that we can observe a slight
correlation of the frequencies of CMV-specific CD8+ T cells with
age in our cohort of CHC patients, which is absent for EBV-
specific CD8+ T cells, again in both cases the change of frequency,
phenotype, and function can be seen for both virus specificities.
Further, also among our healthy cohort individuals are included
that are infected with CMV as well, thus a CMV-specific impact as
described by Brodin et al. (35) does not seem to be themajor force
driving our observations. However, our findings are nevertheless
in line with the publication by Brodin et al., as we also show that
environment influences and other infections (in our case HCV)
seem to alter and shape the immune system.
The presence of assortments of cytokine receptors on effector
and memory antiviral CD8+ T cells enable them to respond
to shifts in the cytokine milieu and may even allow them to
circumvent their requirements for antigen-dependent activation
(36). Recently, effector and memory CD8+ T cells’ sensitivity
to an expansive range of cytokines has been profiled (37). The
effects of inflammatory mediators on the phenotypic changes of
CMV- and EBV-specific CD8+ T cells observed in this study
was therefore not so surprising following these previous reports.
Interestingly, several of the inflammatory cytokines and plasma
proteins from our study here, such as ICAM-1, VCAM-1, IFN-
α2, SDF-1α, and IL-18, that showed elevated concentrations in
patients with CHC compared to healthy individuals have been
associated with T cell activation (38–40). In fact, we show in this
study for the first time that IFN-α2 was not only the differen-
tially dominant component of the HCV-induced inflammatory
mediators but also positively correlated with co-regulatory recep-
tor expression ex vivo. Interestingly, IFN-α2 further caused an
expected upregulation of PD-1 and Tim-3 expression on CMV-
and EBV-specific CD8+ T cells in healthy individuals in vitro.
However, other mediators such as the adhesion molecules ICAM-
1 and VCAM-1 failed to replicate any of these IFN-α2’s ex
vivo behavior or in vitro effects. Nevertheless, these findings
further confirm the profound effect some inflammatory medi-
ators such as type I interferon may have on the phenotype of
antiviral CD8+ T cells. It further suggests a specific importance
of IFN-I in regulating antiviral T cell immunity through co-
regulatory receptor expression in order to protect them against
killing by NK cells as a regulatory immune function as suggested
previously (41).
The expression of 2B4 instead showed a decline of expression
after INF-α2 stimulation in vitro, while the frequency of expres-
sion of PD-1 and Tim-3 was consistently increased. This different
behavior of 2B4 upon stimulation might be based on the fact that
2B4 is not a classical inhibitory receptor, but it rather has a dual
function able to induce at least twodifferent downstream signaling
pathways, which subsequently elicit different cellular responses
(i.e., either activation or inhibition) (42).
Previous studies byWang et al. in patientswith chronic hepatitis
B showed a reduction of PD-1 and Tim-3 expressions on CD8+ T
cells following antiviral treatment against HBV (43). However, to
our knowledge, no study has so far dissected whether the cessa-
tion of inflammation in patients with CHC revert the phenotype
of CMV- and EBV-specific CD8+ T cells hitherto induced by
the inflammatory environment. The introduction of the novel
IFN-free therapy to cure HCV infection allowed us the unique
opportunity to investigate the effects therapy-induced HCV clear-
ance has on co-regulatory receptor expression onCMV- and EBV-
specific CD8+ T cells. Of note, HCV RNA shows a very rapid
decline early after start of IFN-free therapy and the inflammatory
activity of liver disease already dramatically reduces 7–14 days
after therapy start (44) suggesting that cytokine patterns normal-
ize rather soon during therapy. Comparing co-regulatory receptor
expression between baseline and 12weeks after the end of antiviral
therapy, we observed that both the frequency and MFI of PD-
1 expression by CMV- and EBV-specific CD8+ T cells reduced
significantly after viral clearance. While only the frequency of
Tim-3-expressing CMV- and EBV-specific CD8+ T cells expe-
rienced a significant decline, that of 2B4 was reflected only in
its MFI. These differential dynamics of PD-1, Tim-3, and 2B4
with an apparently earlier and faster decline of PD-1 expression is
noteworthy and it would be interesting to see the long-term effects
of successful HCV clearance. Further, this partial normalization
of co-regulatory receptor expression by pathogens unrelated to
HCV following a treatment that directly targets HCV reflects the
development of antigen-independent immune homeostasis upon
antiviral therapy in patients with CHC.
The change of the phenotype of CMV- and EBV-specific
CD8+ T cells in CHC patients is accompanied by an elevated
frequency of cells and an enhanced functionality in vitro. While
the change of phenotype might at least partially be explained by
the influence of IFNα, which is drastically elevated during CHC,
the means behind the increased functionality remains unclear.
One possible explanation might be a shift in the expression of
STAT transcription factors and subsequently induced ISGs, as we
and others could previously show to be the case for the enhanced
functionality of NK cells in CHC patients (25, 45). It might
well be that similar mechanisms also apply for CD8+ T cells as
demonstrated recently in mice (46). However, preliminary data
suggest that mechanism(s) other than IFNα stimulation seems
to drive these changes. Despite a clear decline of plasma IFNα
levels associated with a reversion of the phenotype of CMV-
and EBV-specific CD8+ T cells in CHC patients successfully
treated with the direct-acting antivirals sofosbuvir as shown here,
the frequency and functionality of these cells did not change at
FuW12 (data not shown).
The data presented here show the broad andpervasive influence
HCV has on the immune system and other immune cells, besides
the HCV-specific ones. Here, this manifests itself by the alteration
of the properties of CMV- and EBV-specific CD8+ T cells and
by the change of plasma cytokines in patients with CHC. It is
justified to assume that these effects also extend to other cells
of the adaptive (i.e., besides CMV- and EBV-specific CD8+ T
cells) and innate immune system (e.g., NK cells, dendritic cells,
monocytes). Apart from the hitherto described impact of IFNα,
several other reasons and mechanisms might contribute as well.
For instance, other cytokines and inflammatory mediators ele-
vated or decreased during persistent infectionmight contribute to
the conditioning of immune cells. In this regard, also the homeo-
static proliferation of immune cells regulated by several cytokines
might be affected leading to the here described alterations.
Further, direct antigen-specific effects generated, e.g., by T cell
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cross-reactivity might apply as described for other scenarios (47,
48). Importantly, our data presented here are in line and extend
the influence that viral infections might have on immune cell
populations, phenotype, and function as recently described for
CMV in studies of twin pairs (35) and enlarge the portfolio of
influencing factors to include HCV as well.
In summary, this study presents a two-fold level of relevance.
First, they indicate that a persistent infection with HCV can-
not be considered in isolation as it may have far-ranging effects
on the global CD8+ T cell population as well as on antigen-
specific CD8+ T cell immunity against unrelated pathogens such
as CMV and EBV. Here, persistent HCV-induced up-regulated
expression of co-regulatory receptors PD-1, Tim-3, and 2B4
on in vitro-verified, functionally competent CMV- and EBV-
specific CD8+ T cells. This mechanism suggests that distinct co-
regulatory receptors are expressed concomitantly with various
inflammatory factors, which boosts functionality but negatively
regulate the immune response upon reaching a threshold. Second,
they provide a handle to investigate the mechanisms regulating
epitope-specific CD8+ T cell function in general, which might
be of clinical relevance considering the rather high incidence of
a broad array of co-morbidities observed in patients with CHC.
These data further give insight into the regulation of antiviral
pathogen-specific CD8+ T cell responses, especially during clin-
ically relevant virus co-infections in humans such as HCV/HBV,
HCV/HIV, and HBV/HDV. Given the severity of disease associ-
ated with co-infections and the difficulty in treating same, such
knowledge would particularly be relevant for the development of
better therapeutic options.
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